
36 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Pinto, Medical Oncologist in Stanford, CA?
Dr. Harlan Pinto, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 36 years and is board certified. Dr. Pinto graduated from Yale University School of Medicine and completed his residency at Massachusetts General Hospital. Dr. Pinto is fluent in English and Spanish, and is currently seeing new patients. Dr. Pinto’s practice accepts Medicaid, Medicare, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Pinto’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Pinto?
Dr. Harlan Pinto, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Pinto empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Head & Neck Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Pinto is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Pinto go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Massachusetts General Hospital
Medical School: Yale University School of Medicine
Is Dr. Pinto board certified as a Medical Oncologist?
Yes, Dr. Harlan Pinto, MD is board certified by the American Board of Internal Medicine since 1991, American Board of Internal Medicine since 1986
What languages does Dr. Pinto speak?
Dr. Pinto and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Medical Oncologist like Dr. Pinto typically treat?
As a Medical Oncologist, Dr. Pinto diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Pinto. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Cancer Follow-up Exam
- Cancer
- Post-cancer treatment checkup
- Malignancy surveillance
- Oncology follow-up
ICD-10 Codes:
- Z08: Encounter for follow-up examination after completed treatment for malignant neoplasm
Also known as:
- Oral Cancer
- Mouth Cancer
- Tongue Cancer
- Oral Cavity Cancer
- Tongue Carcinoma
ICD-10 Codes:
- C01: Malignant neoplasm of base of tongue
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Secondary Cancer in Head and Neck Lymph Nodes
- Cancer
- Metastatic Cancer to Neck Lymph Nodes
- Head and Neck Lymph Node Cancer Spread
- Lymph Node Metastasis in Neck
ICD-10 Codes:
- C770: Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
Also known as:
- Throat Cancer
- Oral Cancer
- Oropharyngeal Cancer
- Malignant Neoplasm of Oropharynx
- Pharyngeal Cancer
ICD-10 Codes:
- C109: Malignant neoplasm of oropharynx, unspecified
What procedures does a Medical Oncologist like Dr. Pinto typically perform?
As a Medical Oncologist, Dr. Pinto performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Pinto. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Swallowing Therapy
- Dysphagia Treatment
- Feeding Therapy
- Oral Function Therapy
CPT Codes:
- 92526: Treatment of swallowing dysfunction and/or oral function for feeding
Also known as:
- Flexible Endoscopic Swallowing Evaluation (FEES)
- Swallowing Function Test
- Endoscopy
- Dysphagia Tests
- FEES Test
- Swallowing Endoscopy
- Video Swallowing Study
- Dysphagia Endoscopy
- Dysphagia Evaluation
- Oral Swallowing Assessment
- Pharyngeal Swallowing Test
- Swallowing Study
CPT Codes:
- 92612: Flexible endoscopic evaluation of swallowing by cine or video recording;
- 92610: Evaluation of oral and pharyngeal swallowing function
Also known as:
- Voice Prosthetic Fitting
- Speech Prosthesis Evaluation
- Voice Device Assessment
- Artificial Voice Fitting
CPT Codes:
- 92597: Evaluation for use and/or fitting of voice prosthetic device to supplement oral speech
Also known as:
- Individual Speech and Language Therapy
- Speech-Language Pathology
- Voice Therapy
- Communication Disorder Treatment
- Auditory Processing Therapy
CPT Codes:
- 92507: Treatment Of Speech, Language, Voice, Communication, And/Or Auditory Processing Disorder; Individual
Also known as:
- Flexible Diagnostic Laryngoscopy
- Voice Box Exam
- Flexible Laryngoscope
- Throat Scope
- Diagnostic Throat Exam
CPT Codes:
- 31575: Laryngoscopy, flexible; diagnostic
Does Dr. Pinto accept my insurance?
Dr. Pinto accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Pinto accept in Stanford, CA?
Dr. Pinto in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Advantage
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Medicaid
Medicare
Other Provider Networks
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Pinto's office located?
Recognitions
Publications
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
, 2011
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER
, 2010
In vivo H-1 magnetic resonce spectroscopy of lactate in patients with Stage IV head
, 2008
Excellent local control with stereotactic radiotherapy boost after exterl beam radiotherapy
, 2008
Improved survival of patients with human papillomavirus-positive head
, 2008
Evaluation of patterns of failure
, 2007
Clinical role of F-18-FDG PET
, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers
, 2006
Advanced-staged tonsillar squamous carcinoma
, 2006
Phase II double-blind r
, 2004
Improved local control with stereotactic radiosurgical boost
, 2003
Comparison of the comet assay
, 2003
Estimating D repair by sequential evaluation of head
, 2002
In vivo H-1 MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen
, 2000
D damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
, 1999
Stereotactic radiosurgical boost following radiotherapy in primary sopharyngeal carcinoma
, 1999
Tissue oxygen distribution in head and neck cancer patients
, 1999
Magement of the clinically positive neck in organ preservation for advanced head and neck cancer
, 1998
Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter
, 1995
Head and neck cancers.
, 1995
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
, 2011
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER
, 2010
In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head
, 2008
Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy
, 2008
Improved survival of patients with human papillomavirus-positive head
, 2008
Evaluation of patterns of failure
, 2007
Clinical role of F-18-FDG PET
, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers
, 2006
Advanced-staged tonsillar squamous carcinoma
, 2006
Mature results from a randomized phase II trial of cisplatin plus 5
, 2006
Positron-emission tomography for surveillance of head and neck cancer
, 2005
Long-term results of 100 consecutive comprehensive neck dissections
, 2004
Phase II double-blind r
, 2004
Improved local control with stereotactic radiosurgical boost
, 2003
Comparison of the comet assay
, 2003
Identification of osteopontin as a prognostic plasma marker for head
, 2003
Estimating DNA repair by sequential evaluation of head
, 2002
In vivo H-1 MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen
, 2000
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
, 1999
Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma
, 1999
Tissue oxygen distribution in head and neck cancer patients
, 1999
Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers
, 1998
Management of the clinically positive neck in organ preservation for advanced head and neck cancer
, 1998
Surgical morbidity of neck dissection after chemoradiotherapy in advanced head and neck cancer
, 1997
Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter
, 1995
Distant metastases from head and neck squamous cancer: the role of adjuvant chemotherapy.
, 1995
Head and neck cancers.
, 1995
Head and neck cancer - combined modality therapy and chemotherapy.
CHEMOTHERAPY FOR RECURRENT AND METASTATIC HEAD AND NECK-CANCER
, 1991